Skip to Content
Merck
All Photos(1)

Documents

Z-005

Supelco

Zonisamide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H8N2O3S
CAS Number:
68291-97-4
Molecular Weight:
212.23
EC Number:
200-659-6
MDL number:
MFCD00865316
UNSPSC Code:
41116107
PubChem Substance ID:
329831593
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NS(CC1=NOC2=C1C=CC=C2)(=O)=O

InChI

1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

InChI key

UBQNRHZMVUUOMG-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Related Categories

General description

Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.

Application


  • Analysis of environmental samples: Instrument Response Standard for X-Ray Powder Diffraction was utilized for the dispersive magnetic micro solid phase extraction of pollutants in water samples and creams. This technique is vital for scientists engaged in environmental monitoring and contamination studies (Jalilian et al., 2019).

  • Food safety testing: The standard supported efficient extraction and determination methods for Rhodamine B in food samples, underscoring its importance in food safety and quality control labs focused on consumer health protection (Hu et al., 2019).

  • Advanced material characterization: A core-shell indium (III) sulfide@metal-organic framework nanocomposite used for the extraction of nitro-polycyclic aromatic hydrocarbons employs Instrument Response Standards to ensure accurate characterization of nanocomposite properties, critical for researchers developing new materials (Jia et al., 2018).


Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrea Romigi et al.
Epilepsy & behavior : E&B, 26(2), 170-174 (2013-01-15)
The purpose of this study was to evaluate the effects of zonisamide (ZNS) as adjunctive therapy on sleep-wake cycle and daytime somnolence in adult patients affected by focal epilepsy. Thirteen patients affected by focal epilepsy were recruited to undergo a
D Marazziti et al.
European review for medical and pharmacological sciences, 16(15), 2102-2107 (2013-01-03)
Binge-eating disorder (BED) is a relatively new disorder characterized by binge eating without purging. The purpose of this article is to review the potential use of the recently proposed compounds for the treatment of BED. A medline of published articles
S Dupont et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 29-35 (2012-11-01)
Zonisamide is currently licensed in Europe and the USA for the adjunctive treatment of partial seizures (with or without secondary generalization) in adults, based on the results of four pivotal, randomized, double-blind, placebo-controlled trials. It is also licensed in Europe
Yuto Ueda et al.
Biochemical and biophysical research communications, 428(3), 401-404 (2012-10-30)
The anti-epileptic drug zonisamide is reported to exert beneficial effects in patients with Parkinson's disease. To elucidate the pathophysiological mechanisms underlying the anti-parkinsonism effects of zonisamide, we examined the effect of zonisamide co-administered with levodopa in the striata of rats
M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service